Literature DB >> 19040954

Acute colonic pseudoobstruction in a child with sickle cell disease treated with neostigmine.

Arjun Khosla1, Todd A Ponsky.   

Abstract

Sickle cell disease is a disorder that produces significant morbidity and mortality. Vaso-occlusive pain crises are the most common presenting symptom associated with sickle cell patients. A rare, yet important to recognize, complication of sickle cell disease is acute colonic pseudoobstruction, also known as Ogilvie's syndrome. These patients may present with symptoms that are difficult to distinguish from other etiologies of abdominal pain, but a thorough diagnostic workup can provide important clues. Furthermore, there is no agreement on optimal treatment of pseudoobstruction. We report the first pediatric case of acute pseudoobstruction secondary to sickle cell disease that was treated successfully with neostigmine. Early recognition of this phenomenon is important as it alters patient management, can be treated medically, and may avoid unnecessary surgical intervention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19040954     DOI: 10.1016/j.jpedsurg.2008.07.030

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  3 in total

1.  Neostigmine for the treatment of acute colonic pseudo-obstruction (ACPO) in pediatric hematologic malignancies.

Authors:  Jae-Wook Lee; Kyong-Won Bang; Pil-Sang Jang; Nak-Gyun Chung; Bin Cho; Dae-Chul Jeong; Hack-Ki Kim; Soo-Ah Im; Gye-Yeon Lim
Journal:  Korean J Hematol       Date:  2010-03-31

2.  Evaluation of intravenous neostigmine infusion on tolerance of enteral nutrition in Intensive Care Unit patients.

Authors:  Omid Aghadavoudi; Saeed Abbasi; Parviz Kashefi; Mohammad Golparvar; Mohammadreza Habibzade; Shadi Kazemi
Journal:  J Res Med Sci       Date:  2013-09       Impact factor: 1.852

3.  Ogilvie syndrome in a 8 year old girl after laparoscopic appendectomy.

Authors:  Giulia Gortani; Federica Pederiva; Lydie Ammar; Elisabetta Miorin; Giovanna Tonin; Giulia Dobbiani; Elena Marcuzzi; Egidio Barbi
Journal:  BMC Pediatr       Date:  2019-03-20       Impact factor: 2.125

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.